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Abstract
The limited efficacy of the BCG vaccine against tuberculosis is partly due to the missing expression of immunogenic
proteins. We analyzed whether the addition to BCG of ESAT-6 and HspX, two Mycobacterium tuberculosis (Mtb) antigens,
could enhance its capacity to activate human dendritic cells (DCs). BCG showed a weak ability to induce DC maturation,
cytokine release, and CD4+ lymphocytes and NK cells activation. The addition of ESAT-6 or HspX alone to BCG-stimulated DC
did not improve these processes, whereas their simultaneous addition enhanced BCG-dependent DC maturation and
cytokine release, as well as the ability of BCG-treated DCs to stimulate IFN-c release and CD69 expression by CD4+
lymphocytes and NK cells. Addition of TLR2-blocking antibody decreased IL-12 release by BCG-stimulated DCs incubated
with ESAT-6 and HspX, as well as IFN-c secretion by CD4+ lymphocytes co-cultured with these cells. Moreover, HspX and
ESAT-6 improved the capacity of BCG-treated DCs to induce the expression of memory phenotype marker CD45RO in naı¨ve
CD4+ T cells. Our results indicate that ESAT-6 and HspX cooperation enables BCG-treated human DCs to induce T
lymphocyte and NK cell-mediated immune responses through TLR2-dependent IL-12 secretion. Therefore ESAT-6 and HspX
represent good candidates for improving the effectiveness of BCG vaccination.
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Introduction
Mycobacterium tuberculosis (Mtb), the etiological agent of
tuberculosis, modulates dendritic cell (DC) and T lymphocyte
functions in diverse ways. Treatment of immature monocyte-
derived DCs with Mtb elicits the formation of mature DCs, which
produce several cytokines and activate T lymphocytes [1].
However, Mtb also alters DC differentiation [2], maturation and
cytokine secretion [3–4], in order to survive inside the host
organism. Mtb secretes numerous proteins that subvert host
defenses [5] and impair the development of protective immunity
[6–7]. Among such are 16-kDa heat shock protein (HspX)
(Rv2031c) [6] and early secreted antigenic target protein-6
(ESAT-6) (Rv3875) [7]. HspX, also known as a-crystallin, is
secreted during the latency phase of mycobacterial growth and is
required for the persistence of Mtb in the environment of the
macrophage phagosome [8]. HspX also plays a role in slowing
Mtb growth [9] and generates IFN-c-producing T cells in the
peripheral blood mononuclear cells (PBMC) of Mtb-exposed
individuals [8].
ESAT-6, a highly immunogenic secreted protein [10], is able to
lyse alveolar epithelial cells and macrophages [11], destabilize
phagolysosomes [12], and activate the inflammasome [13].
Recently, Romagnoli et al. demonstrated that ESAT-6 is involved
in the ability of Mtb to escape the human DC phagosome [14].
Also, ESAT-6 is known to induce the PBMC of tuberculosis-
bearing patients to produce IFN-c and chemokines [15–16].
Furthermore, recombinant DNA vaccine encoding ESAT-6 elicits
a strong Th1 response in mice [17]. Vaccination with a fusion
protein composed of ESAT-6 and Antigen 85B, a protein
belonging to the Mtb Antigen 85 complex [18], activates DCs
and Th1/Th17 cell responses in mouse models [19–21].
Collectively, these findings suggest that HspX and ESAT-6 may
be promising candidates for vaccines against tuberculosis,
although Wang et al. have found that high doses of ESAT-6
decrease Th1/Th17 cell activity [22], indicating that the optimal
design of such vaccines requires further investigation to better
characterize the effects these antigens have on immune cells.
Bacillus Calmette-Guerin (BCG), the only tuberculosis vaccine
currently used, is a live, attenuated strain obtained from virulent
Mycobacterium bovis, closely related to Mtb. Its attenuation
results in the deletion of region of difference 1 (RD1), a 9.5 Kb
region encoding nine genes, including ESAT-6. RD1 is absent
from all BCG substrains but present in virulent M. bovis and M.
tuberculosis [7]. Given that BCG often fails to protect against
pulmonary tuberculosis in adults [23], recent research has been
focused on improving the effectiveness of BCG. One way to do this
is by introducing Mtb antigens absent from BCG, such as ESAT-
6. Another is to induce the overexpression of immunogenic
proteins not expressed throughout all phases of Mtb infection,
such as HspX [24]. Majlessi et al. demonstrated that the
reintroduction of RD1 into BCG improved its capacity to protect
mice against Mtb challenge [25]. Similarly, HspX augments the
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immune stimulatory effect of BCG. In fact, HspX based vaccines
enhance the ability of BCG to stimulate immune response in mice,
providing a better protection against Mtb [8,26–28].
Therefore, many reports indicate that ESAT-6 and HspX
improve the capacity of BCG to activate the host immune system
against Mtb in mouse models. However, little is known about the
effect of these antigens on human immune cells stimulated with
BCG. Indeed, further studies are needed to elucidate a possible
cooperation between ESAT-6, HspX, and BCG in human DCs
function and to investigate the dual role of Mtb antigens as vaccine
candidates and as virulence factors inhibiting the immune system
[29]. For these reasons, we analyzed the effects of BCG, ESAT-6
and HspX on the maturation and function of human primary
DCs. In particular, we investigated whether the addition of ESAT-
6 and HspX antigens, alone or in combination, could improve the
ability of BCG to induce DC maturation and/or cytokine release,
as well as the capacity of BCG- and antigen-treated DCs to
stimulate T lymphocytes and Natural Killer (NK) cells. Also we
sought to identify the DC receptors and cytokines responsible for
the effects of ESAT-6 and HspX. Our results indicate that ESAT-
6 and HspX represent possible candidates for improving the
effectiveness of BCG on human immune cells.
Figure 1. Effect of HspX and ESAT-6 on BCG-induced cytokine secretion by DCs. Monocytes were treated (5 days) with 50 ng/ml GM-CSF
and 20 ng/ml IL-4 to obtain immature DCs, that were subsequently cultured (24 hrs) in the absence (CTRL) or presence of 50 mg/ml BCG, alone or
combined with 10 mg/ml HspX and/or 10 mg/ml ESAT-6. DCs were also cultured with 50 mg/ml Mtb as a positive control. Release of the indicated
cytokines in culture supernatants was evaluated by ELISA. Results are expressed as the mean value+SD of seven independent experiments. Statistical
analysis: DCs treated with BCG alone vs BCG plus HspX and ESAT-6 added alone or in combination; ns P.0.05, *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0075684.g001
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Materials and Methods
Reagents and Antibodies
RPMI 1640 and low-endotoxin fetal bovine serum (FBS) were
obtained from Lonza (Walkersville, MD). Recombinant human
granulocyte-macrophage colony-stimulating factor (GM-CSF) and
human IL-4 were purchased from Miltenyi Biotec (Bergisch
Gladbach, Germany). Gamma-irradiated whole cells of M.
tuberculosis (strain H37Rv) were obtained through BEI Resources,
NIAID, (NIH NR-14819); a-crystallin (Gene Rv2031c), a purified
native protein from M. tuberculosis (strain H37Rv, NR-14860)
was provided by NIH Biodefense and Emerging Infections
Research Resources Repository, NIAID, NIH; M. bovis BCG
kindly provided by Dr. G. Batoni (Dept. Of Experimental
Pathology, Medical Biotechnology, Infectivology and Epidemiol-
ogy, University of Pisa, Italy) was prepared as described in [30]
and killed at 55uC for 30 minutes; rdESAT-6 was provided by
Statens Serum Institut (Copenhagen, Denmark). Ultrapure
lipolysaccharide (LPS) from E. coli (0111: B4 strain) and
palmitoyl-3-cysteine-serine-lysine-4 (Pam3CSK4) were purchased
from InvivoGen (San Diego, CA). All of the above reagents
contained less than 0.125 endotoxin units/ml, as measured by the
Limulus amebocyte lysate assay (Microbiological Associates,
Walkersville, MD). Flow cytometric analysis was performed using
the following mouse anti-human antibodies: CD83 (HB15e), CD4
(SK3) and CD1a (HI149) (Becton Dickinson, San Jose, CA); CD56
(HCD56), CD69 (FN50), CD86 (T2.2), HLA-DR (L243) and IFN-
c (4S.B3) (Biolegend, San Diego, CA); CD4 (VIT4), CD45RO
(UCHLI), CD45RA (T6D11) (Miltenyi Biotec); IL-17AF
(20LJS09) (eBioscience, San Diego, CA). The blocking antibodies
were: anti- Toll-like Receptor (TLR) 2 (T2.5) (eBioscience, San
Diego, CA); anti-IL12p70 (20C2) [31–32] kindly provided by Dr.
G. Trinchieri (Center for Cancer Research, NCI, Frederick, MD).
Monoclonal mouse IgG1 (eBioscence) was used as the isotype
control antibody.
Preparation and Culture of DCs, Lymphocytes and NK
Cells
After written informed consent and upon approval of the ethical
committee, human blood was collected from healthy volunteers at
the blood bank of the University of Verona. Monocytes were
isolated from buffy coats by Ficoll-Hypaque and Percoll (GE
Healthcare Life Science) density gradients and purified using the
human monocyte isolation kit II (Miltenyi Biotec), as previously
described [1]. The final monocyte population was 99% pure, as
measured by FACS analysis. To generate immature DCs,
monocytes were incubated at 37uC in 5% CO2 for 5–6 days at
16106/ml in 6-well tissue culture plates (Greiner, Nu¨rtingen,
Germany) in RPMI 1640, supplemented with heat-inactivated
10% low endotoxin FBS, 2 mM L-glutamine, 50 ng/ml GM-CSF,
and 20 ng/ml IL-4. The final DC population was 98% CD1a+, as
measured by FACS analysis.
NK cells and autologous total and naı¨ve CD4+ T cells were
isolated from the lymphocyte fraction of the Percoll gradient with
EasySepTM Negative Selection Human Cell Enrichment kits
(StemCell Technologies, Vancouver, Canada). The final popula-
tions were 98% pure, as measured by FACS analysis. To preserve
T cells during differentiation of monocytes into DCs, the cells were
spinned down, resuspended in freezing medium (low endotoxin
FBS +10% DMSO), and kept in a liquid nitrogen freezer.
To induce cell maturation and cytokine release, DCs were
treated for 24 hrs with: Mtb (50 mg/ml), Pam3CSK4 (10 mg/ml),
LPS (100 ng/ml), BCG (50 mg/ml) alone or combined with HspX
(10 mg/ml) and/or ESAT-6 (10 mg/ml). For experiments with
blocking antibodies, immature DCs were pre-incubated for
15 min at room temperature with anti-IL-12p70 or anti-TLR2
antibodies and with an isotype antibody IgG1. In order to study
their effects on T lymphocytes, mature DCs were co-cultured for
7 days with total CD4+ T cells or for 9 days with naı¨ve CD4+ T
cells. The DCs:T-cell ratio was 1:10. NK cells were incubated for
24 hrs with conditioned media (added to 1:1 ratio) from DCs
treated with Mtb (50 mg/ml) or BCG (50 mg/ml) alone or
combined with HspX (10 mg/ml) and/or ESAT-6 (10 mg/ml).
For the experiments with blocking antibodies, the supernatants
were pre-incubated for 15 minutes at room temperature with anti-
IL-12p70 and with an isotype antibody IgG1.
ELISA Assay
Cytokine production in culture supernatants was determined by
ELISA according to the manufacturer’s instructions: IL-6 (range
8–800 pg/ml) purchased from ImmunoTools GmbH, (Friesoythe,
Germany); IL-12 (range 4–500 pg/ml), IL-1b (range 4–500 pg/
ml), IL-23 (range 15–2000 pg/ml), TNF-a (range 4–500 pg/ml),
IL-10 (range 2–300 pg/ml), IFN-c (range 4–500 pg/ml), IL-17AF
(range 30–4000 pg/ml), purchased from eBioscience (San Diego,
CA).
Flow Cytometric Analysis
For surface staining, cells were washed twice with PBS salt
solution and incubated for 30 min with 10% human serum to
prevent non-specific binding. For direct immunofluorescence
staining, mouse anti-human CD1a, CD83, CD86, HLA-DR,
CD69, CD56, CD4, CD45RO, and CD45RA were used (see
reagents). Following stimulation with 20 ng/ml PMA, 1 mM
ionomycin and 10 mg/ml brefeldin A (Biolegend) for the final
6 hrs of culture [33], cytokine intracellular staining of T cells was
performed. After staining with a fluorescent-conjugated antibody
anti-CD4, the cells were incubated with fixation/permeabilization
buffer (420801 and 421002, Biolegend). Subsequently, they were
stained with anti-IL17AF and IFN-c fluorescent-conjugated
antibodies (see reagents). Annexin-V (Roche Applied Science,
Indianapolis, IN) was used to detect apoptotic cells. Samples were
acquired on a seven-color MACSQuant Analyzer (Miltenyi
Biotec) and analyzed with FlowJo 10 (TreeStar).
Statistical Analysis
Data are expressed as the mean+SD. Statistical analyses,
including Student’s t test and one-way ANOVA with Bonferroni
test, were performed using SigmaStat 3.0 for Windows (Systat
Software, San Jose, CA).
Results
ESAT-6 and HspX Improve the Ability of BCG to Stimulate
Human DC Maturation and Pro-inflammatory Cytokine
Release
The interaction of DCs with pathogenic microorganisms or
their derivatives elicits the production of various cytokines that
orchestrate the immune response [34]. We examined the capacity
of BCG, ESAT-6 and HspX to induce cytokine secretion by DCs.
For this purpose, monocytes were cultured for 5 days with GM-
CSF and IL-4 to obtain immature DCs. The latter cells were
challenged with BCG, ESAT-6 or HspX, as well as with Mtb as a
positive control [1]. The bacteria and antigen doses were selected
on the basis of preliminary dose-response experiments (results not
shown). After 24-hr treatment, culture supernatants were collected
and cytokine secretion was analyzed by ELISA. We found that
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Figure 2. Effect of HspX and ESAT-6 on BCG-elicited DC maturation. DCs were treated with Mtb as a positive control and with BCG alone or
combined with HspX and ESAT6. Cells were collected after 24 hrs culture and the expression of maturation markers was analyzed by flow cytometry.
(A) Histograms illustrate CD83, CD86 and HLA-DR surface expression in CD1a+ cells and the MFI. Filled histograms represent the control, open
histograms indicate treated cells. One of four different experiments is presented. (B) Bar graphs show the CD83, CD86 and HLA-DR MFI value of the
four experiments expressed as fold change (MFI FC) over control (CTRL). Statistical analysis: CTRL vs BCG alone; BCG alone vs BCG plus HspX and
ESAT6; ns P.0.05, *P,0.05.
doi:10.1371/journal.pone.0075684.g002
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Figure 3. ESAT-6 and HspX enable BCG-stimulated DCs to elicit IFN-c secretion and to enhance CD69 expression in CD4+ T
lymphocytes. DCs were stimulated for 24 hrs with Mtb or BCG alone or with ESAT-6 and/or HspX, and then co-cultured with autologous CD4+ T
lymphocytes for 7 days. (A) Evaluation of IFN-c and IL-17AF secretion in culture supernatants by ELISA. Results are expressed as the mean+SD of
seven independent experiments. Statistical analysis: DCs treated with BCG alone vs BCG plus HspX and/or ESAT-6; ns P.0.05, *P,0.05. (B) Evaluation
of IFN-c and IL-17AF-production detected by intracellular staining and analyzed by FACS in Annexin V2/CD4+/CD1a2 cells. Zebra plots illustrate one
representative experiment and the percentage of positive cells (left); bar graphs show the mean+SD of three independent experiments (right).
Statistical analysis: DCs treated with BCG alone vs BCG plus HspX and/or ESAT-6; ns P.0.05, *P,0.05, **P,0.01. (C) Flow cytometric analysis of CD69
expression in Annexin V2/CD4+/CD1a2 cells. Panels illustrating one representative experiment with the MFI are shown on the left. Filled histograms
represent the control, open histograms represent treated cells. Bar graphs representing the MFI mean value+SD of three experiments expressed as
fold change over control (MFI FC) are shown on the right. Statistical analysis: DCs treated with BCG vs BCG/HspX/ESAT-6; **P,0.01.
doi:10.1371/journal.pone.0075684.g003
HspX and ESAT6 Improve BCG-Induced Immune Response
PLOS ONE | www.plosone.org 5 October 2013 | Volume 8 | Issue 10 | e75684
BCG induced a weak release of these cytokines (Fig. 1). DCs
challenge with a purified HspX and/or a recombinant ESAT-6
protein did not affect the cytokine production (results not shown).
As reintroduction of the ESAT-6 gene restores the ability of BCG
to activate mouse immune cells [25], we wanted to determine
whether the addition of the ESAT-6 protein, alone or simulta-
neously with HspX, which also augments the immune stimulatory
effects of BCG in mice [8,24], could increase human DC response
to BCG stimulation. We found that the addition of HspX alone to
BCG-treated DCs did not significantly influence cytokine release,
whereas ESAT-6 increased the secretion of IL-23 but not the other
cytokines (Fig. 1). Interestingly, the simultaneous addition of HspX
and ESAT-6 to BCG-stimulated DCs significantly increased the
secretion of IL-12, IL-1b, IL-23, IL-6, and TNFa but not IL-10, as
compared to DCs challenged with BCG alone or when combined
with either antigen separately (Fig. 1).
The interaction between immature DCs and pathogens induces
their maturation, enabling DCs to activate immune effectors cells
[34]. This leads to the formation of DCs with increased CD83,
CD86 and HLA-DR expression on the membrane surface [35–
36]. Consequently, we analyzed the maturation of the DCs
already used for ELISA (Fig. 1) and found that BCG did not
induce significant CD83 and CD86 up-regulation and that it
inhibited HLA-DR basal expression, as compared to untreated
DCs (Fig. 2A and B). However, the simultaneous addition of
ESAT-6 and HspX to BCG-treated DCs significantly increased
CD83, CD86, and HLA-DR expression, as compared to DCs
incubated with BCG alone (Fig. 2A and B). DCs did not mature
upon cell stimulation with ESAT-6 or HspX in the absence of
BCG nor did they mature following cell stimulation with BCG and
either ESAT-6 or HspX alone (results not shown).
ESAT-6 and HspX Enable BCG-treated DCs to Activate
CD4+ Lymphocytes
Mature DC are known to regulate the activity of T lymphocytes
which play a prominent role in defensive mechanisms against
tuberculosis [37]. As ESAT-6 and HspX improved the BCG-
dependent DC cytokine release and maturation (Fig. 1 and 2), we
hypothesized that these antigens could influence the capacity of
DCs to regulate T lymphocyte activity. Therefore, we investigated
whether treatment with BCG, HspX and/or ESAT-6 would
enable DCs to induce Th1 and/or Th17 response. For this
purpose, DCs induced to maturation with Mtb or BCG, alone or
combined with ESAT-6 and/or HspX, were co-cultured with
autologous CD4+ lymphocytes. After 7 days the culture superna-
tants were assayed by ELISA for the presence of IFN-c and IL-
17AF. This time point was chosen on the basis of previous time
course viability assays (results not shown). Figure 3A shows that
DCs incubated with Mtb induced remarkable IFN-c and IL-17AF
production by T cells, whereas DCs stimulated with BCG, alone
or in combination with either HspX or ESAT-6, showed a weak
ability to activate these responses. However, DCs incubated with
BCG and both HspX and ESAT-6 induced significantly higher
IFN-c secretion by CD4+ lymphocytes than that elicited by DCs
challenged with BCG alone or when combined with either antigen
separately (Fig. 3A). In contrast, IL-17AF secretion induced by
DCs incubated with BCG/HspX/ESAT-6 was comparable to
that observed when DCs were treated with BCG alone or in
combination with either antigen separately.
Among the classical Th1 and Th17 cells responsible for IFN-c
and IL-17 production, respectively, a Th17/Th1 subset able to
produce both IL-17 and IFN-c has been discovered [38]. In order
to identify the T cell subsets responsible for cytokine production
(Fig. 3A), we performed IFN-c and IL-17AF intracellular staining.
Cell viability was evaluated by Annexin V staining. FACS analysis
demonstrated that DC stimulated with BCG, alone or in
combination with either HspX or ESAT-6 separately, showed a
weak ability to induce Th1, Th17, and Th17/Th1 differentiation,
whereas DC incubated with BCG/HspX/ESAT-6 induced a
remarkable development of all these Th cell subsets. Notably, this
effect was comparable to that obtained upon DCs challenge with
Mtb (Fig. 3B). These results demonstrate that IFN-c and IL-17AF,
as detected by ELISA (Fig. 3A), are produced by Th1 and Th17,
respectively, but also by Th17/Th1 cells. Although DCs incubated
with BCG/HspX/ESAT-6 induced a significant increase in IL-
17AF-producing cells as compared to BCG-treated DCs (Fig. 3B),
the amount of IL-17AF detected in the culture media of these cells
was not significantly different (Fig. 3A). This discrepancy could be
due to the fact that a very low percentage of IL-17AF-producing
cells is insufficient to generate significant IL-17AF protein
secretion in culture media.
Control experiments with CD4+ lymphocytes stimulated with
various combinations of BCG, ESAT-6 and HspX in the absence
of DCs did not elicit IFN-c or IL-17AF secretion (results not
shown), suggesting that BCG, ESAT-6 and HspX do not directly
modulate T cell activation. Moreover, DCs alone treated with
Figure 4. The ability of BCG, ESAT-6 and HspX-treated DCs to elicit IFN-c secretion by CD4+ cell is mediated by IL-12. DCs pre-
incubated (open bars) or not (filled bars) with 20 mg/ml IL-12p70 blocking antibody were stimulated for 24 hrs with Mtb or with BCG alone or with
ESAT-6 and HspX and then co-cultured for 7 days with autologous CD4+ T lymphocytes. IFN-c and IL-17AF secretion was analyzed by ELISA. Results
are expressed as the mean+SD of five experiments. Statistical analysis: antibody-treated vs antibody-untreated cells; ns P.0.05, *P,0.05.
doi:10.1371/journal.pone.0075684.g004
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various combinations of BCG, HspX, and ESAT-6 did not secrete
IFN-c or IL-17AF (results not shown), thus ruling out their
contribution to cytokine production after co-culture of DCs with T
lymphocytes.
Subsequently, we analyzed the effect of BCG, HspX and
ESAT-6 on the ability of DCs to induce the expression of CD69, a
well-known T lymphocyte activation marker, in CD4+ cells [39].
We found that BCG-treated DCs did not elicit CD69 expression,
whereas the simultaneous addition of BCG, HspX and ESAT-6
up-regulated this activation marker in CD4+ cells co-cultured with
DCs. Notably, this effect was comparable to that obtained upon
DCs challenge with Mtb (Fig. 3C).
TLR2-dependent IL-12 Secretion is Involved in CD4+
Lymphocyte Activation by DCs Stimulated with BCG,
ESAT-6 and HspX
It is well accepted that IL-12 plays a key role in the induction of
IFN-c secretion by T lymphocytes [40]. We hypothesized that
among the cytokines secreted upon DCs treatment with BCG/
ESAT-6/HspX, IL-12 could be the one mainly involved in
stimulating IFN-c secretion by T lymphocytes (Fig. 3A). Conse-
quently, we wanted to examine whether IL-12 blockage could
affect IFN-c secretion. To test this hypothesis, the cells were
incubated with an antibody able to bind IL-12 p70 and,
specifically, to block IL-12 without affecting IL-23 [31–32].
Figure 5. TLR2 is involved in IL-12-dependent IFN-c secretion
by CD4+ cells co-cultured with ESAT-6, HspX and BCG-treated
DCs. DCs cultured in the absence (filled bars) or presence (open bars)
of 5 mg/ml TLR2-blocking antibody were treated for 24 hrs with Mtb,
BCG alone or combined with HspX and ESAT6, 10 mg/ml Pam3CSK4
(Pam3) or 100 ng/ml LPS. (A) Supernatants were collected and IL-12
release was analyzed by ELISA. Results are the mean value+SD of four
experiments. Statistical analysis: antibody-treated vs antibody-untreat-
ed cells, ns P.0.05, *P,0.05, ***P,0.001. (B) DCs were co-cultured with
autologous CD4+ T lymphocytes. After 7 days, culture supernatants
were collected and analyzed by ELISA for IFN-c release. Results are the
mean+SD of three experiments. Statistical analysis: antibody-treated vs
antibody-untreated cells, ns P.0.05, *P,0.05.
doi:10.1371/journal.pone.0075684.g005
Figure 6. CD45RO and CD45RA modulation in CD4+ naı¨ve T
cells. DCs pre-treated for 24 hrs with Mtb or with BCG alone or
combined with HspX and ESAT6 were co-cultured with purified CD4+
naı¨ve T cells. After 9 days, the surface expression of CD45RO and
CD45RA was analyzed by flow cytometry in Annexin V2/CD4+/CD1a2
cells. (A) Zebra plots illustrate one representative experiment with the
percentage of CD45RO positive cells. (B) Bar graph shows the CD45RO
and CD45RA MFI mean+SD of three experiments expressed as fold
change over control (MFI FC). Statistical analysis: BCG vs BCG plus HspX
and ESAT-6, *P,0.05.
doi:10.1371/journal.pone.0075684.g006
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Figure 4 shows that IL-12 blockage decreased the ability of DCs
challenged with BCG, alone or combined with HspX and ESAT-
6, to induce IFN-c secretion by CD4+ lymphocytes. Moreover, the
antibody increased IL-17AF production by CD4+ lymphocytes
cultured with DCs stimulated with BCG/HspX/ESAT-6 (Fig. 4).
Similar results were obtained from control experiments with DCs
incubated with the antibody and stimulated with Mtb (Fig. 4). An
isotype matched antibody did not affect the capacity of DCs to
modulate cytokine production by T cells (results not shown). These
results indicate that ESAT-6 and HspX increase IFN-c release by
T lymphocytes mainly by enhancing IL-12 secretion by co-
cultured BCG-conditioned DCs. Moreover, the ESAT-6- and
HspX-dependent increase in IL-12 release inhibited IL-17AF
secretion, shifting the lymphocytes toward a Th1 response
characterized by a prevalent IFN-c release.
It has been reported that ESAT-6 [41–42] and some Mtb heat
shock proteins [43] bind TLR2, which plays a critically important
role in the interaction between DCs and mycobacteria [44].
Therefore, we explored whether a TLR2-blocking antibody could
affect BCG, ESAT-6 and HspX cooperation. We found that the
antibody reduced IL-12 release by BCG-treated DCs stimulated
with ESAT-6 and HspX (Fig. 5A). The antibody also suppressed
IL-12 release by both Mtb-treated DCs and control DCs
stimulated with Pam3CSK4, a specific TLR2 agonist. In contrast,
the antibody did not affect IL-12 production by DCs stimulated
with LPS, a TLR4 agonist (Fig. 5A), indicating that it specifically
blocks TLR2-dependent IL-12 release. An isotype matched
antibody did not affect IL-12 release by DCs stimulated with
BCG/ESAT-6/HspX, Mtb, Pam3CSK4 or LPS (results not
shown). Interestingly, the TLR2-blocking antibody also decreased
the ability of DCs incubated with Mtb, as well as with BCG/
HspX/ESAT-6, to induce IFN-c secretion by co-cultured CD4+
lymphocytes (Fig. 5B). Additionally, the capacity to induce IFN-c
secretion by CD4+ lymphocytes was inhibited by the antibody only
in Pam3CSK4-stimulated DC and not in LPS-treated DCs
(Fig. 5B).
DCs Challenged with BCG, HspX and ESAT-6 Induce a
Memory Phenotype in Naı¨ve T Lymphocytes
Human CD4+ lymphocyte preparations contain both naı¨ve and
memory T cells. Hence, we examined whether DCs incubated
with BCG/HspX/ESAT-6 were able to induce a memory
phenotype in naı¨ve T cells. For this purpose, we isolated naı¨ve
CD4+ T cells (CD45RA+/CD45RO2) and co-cultured them with
Figure 7. Effect of BCG plus ESAT-6 and HspX on DC-mediated IFN-c release and CD69 expression by NK cells. Culture supernatants of
DCs treated as described in Figure 1 were incubated without (filled bars) or with (open bars) 20 mg/ml IL-12-blocking antibody and then added to
purified NK cells. After 24 hrs, IFN-c release was measured by ELISA (A and C) and CD69 expression was analyzed by flow cytometry in CD56+ cells (B).
(A) Results are the mean+SD of three experiments. Statistical analysis: NK cells stimulated with supernatants from BCG-treated DCs vs supernatants of
BCG plus HspX and/or ESAT-6-treated DCs; ns P.0,05, *P,0.05. (B) Panels illustrate one representative experiment and the bar graph shows the MFI
mean value+SD of three experiments expressed as fold change over control (MFI FC). Filled histograms represent the control; open histograms
represent the treated cells. Statistical analysis: NK cells stimulated with supernatants from BCG-treated DCs vs supernatants of BCG/HspX/ESAT-6-
treated DCs, *P,0.05; (C) Results are the mean+SD of three experiments. Statistical analysis: IL-12-blocking antibody-treated supernatants vs
untreated supernatants; ns P.0,05, *P,0.05.
doi:10.1371/journal.pone.0075684.g007
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DCs stimulated with BCG, alone or with HspX and ESAT-6, as
well as with Mtb as a positive control. After 9 days, we analyzed by
flow cytometry the expression of CD45RO and CD45RA, well-
known memory and naı¨ve T cell markers, respectively [45]. As
shown in Figure 6A and B, BCG treatment did not lead to a
significant expansion of CD45RO+ cells (22.9%), as compared to
untreated cells (21.5%). Interestingly, we observed that the
simultaneous addition of HspX and ESAT-6 enabled BCG-
treated DCs to induce the expansion of memory CD4+ T cell
population (51.4%) (Fig. 6A and B).
ESAT-6 and HspX Improve the Ability of BCG-treated DCs
to Activate NK Cells through Induction of IL-12 Release
Soluble mediators released by mature DCs activate NK cells
involved in the host defense against micobacteria [46]. We
explored whether cytokines released in culture supernatants by
DCs in the experimental conditions depicted in Figure 1 induced
NK cell activation. For this purpose, NK cells were isolated and
incubated with conditioned media collected from the cultures of
DCs treated with BCG, alone or combined with ESAT-6 and/or
HspX, as well as with Mtb as a positive control. IFN-c secretion
was analyzed by ELISA and expression of the CD69 activation
marker was evaluated by FACS analysis. We found that the
incubation with conditioned media from Mtb-treated DCs
induced IFN-c release by NK cells (Fig. 7A), whereas culture
supernatants from DCs stimulated with BCG, added alone or in
combination with either HspX or ESAT-6 separately, showed a
slight ability to activate such a response (Fig. 7A). In contrast,
media collected from cultures of DCs treated with BCG/HspX/
ESAT-6 elicited a significantly higher IFN-c release than that
observed in the media from DCs incubated with BCG added alone
or with the either antigen (Fig. 7A). The FACS analysis revealed
that supernatants from DCs treated with Mtb or BCG/HspX/
ESAT-6, but not with BCG alone, induced CD69 expression by
NK cells (Fig. 7B). Direct NK cell stimulation with Mtb, BCG,
ESAT-6 and HspX did not induce IFN-c release or CD69
expression (results not shown), suggesting that NK cell activation is
mediated by soluble agonists released by mycobacteria- and
antigen-activated DCs.
As IL-12 plays an essential role in the NK cell activation [47],
we analyzed the effect of the IL-12-blocking antibody, already
used for the experiments shown in Fig. 4, on NK cell responses
induced by culture media of DCs stimulated with BCG and the
two antigens. Antibody addition to the media from DCs treated
with Mtb or BCG/HspX/ESAT-6 decreased the ability of these
supernatants to induce IFN-c release by NK cells (Fig. 7C). An
isotype matched antibody did not affect the capacity of culture
media from DCs treated with Mtb or with BCG/HspX/ESAT-6
to stimulate IFN-c release by NK cells (results not shown). These
results indicate that ESAT-6 and HspX enhance NK cell
activation by increasing IL-12 release from BCG-treated DCs.
Discussion
Here we demonstrate that BCG shows a scarce ability to induce
human DC maturation and cytokine release, which results in a
subsequent weak capacity of DCs to induce CD4+ lymphocytes
and NK cell activation. Our findings confirm previous results
showing a weak immune cell response to BCG [29] which might,
in part, explain why BCG vaccination does not produce strong
and persistent protection against adult pulmonary tuberculosis.
We have also shown that ESAT-6 and HspX, per se or when
separately added to BCG-treated DC, do not significantly affect
DC activity. However, ESAT-6 and HspX cooperate in increasing
BCG-dependent DCs maturation and pro-inflammatory cytokine
secretion, suggesting that the addition of HspX and ESAT-6 could
attribute to BCG important immune stimulatory characteristics.
Conversely, anti-inflammatory cytokine IL-10 secretion did not
significantly increase, indicating that cooperation between ESAT-
6 and HspX results in a preferential release of immune response-
enhancing mediators. This indication is supported by the result
that upon stimulation with both these antigens and BCG, DCs
become capable to activate CD4+ lymphocytes and NK cells.
Interestingly, this treatment rendered DCs able to induce a
memory phenotype in naı¨ve T lymphocytes, further corroborating
the suggestion that HspX and ESAT-6 enhance the ability of BCG
to activate immune responses.
Our findings are very important considering that the ability to
elicit immunological memory is an essential requisite of vaccine
components. Our data are consistent with previous reports that
reintroduction of the ESAT-6 gene into BCG improves its
capacity to protect mice against Mtb challenge [25].
It has been reported that the addition of either HspX [8] or
ESAT-6 [15] alone activates IFN-c production by human PBMC.
These effects were obtained with cells from patients with
tuberculosis, whereas healthy or BCG-vaccinated subjects were
less or not responsive to HspX [8] or ESAT-6 [15]. It is
conceivable, therefore, that in the absence of Mtb infection,
stimulation with either HspX or ESAT-6 alone does not efficiently
activate immune cells and/or boost BCG-induced cell responses.
Our results suggest that a more effective stimulation might be
obtained by treating human immune cells from healthy subjects
with BCG and both the antigens.
It has been demonstrated that a recombinant DNA vaccine
encoding ESAT-6 elicits a strong Th1 response in mouse models
[17], and that HspX-based vaccines enhance the ability of BCG to
stimulate immune response [8,26–28]. In our study, however,
neither ESAT-6 nor HspX alone activated immune cells on their
own or when either was combined with BCG. This discrepancy
indicates that, differently from murine cells, stimulation with both
ESAT-6 and HspX is needed to induce human immune cell
response.
Conversely, our findings are in line with previous results
showing that vaccination with fusion protein composed of two Mtb
antigens efficiently increases DCs and T cell response [19–21].
Importantly, we observed that DCs are necessary for the activation
of T lymphocytes and NK cells by Mtb, BCG and antigens. This
finding indicates that the effect of these agonists is mediated by
DCs. A number of studies have suggested that DCs reinforce
cellular immune response against Mtb. In fact, DCs are very well
represented at the sites of Mtb infection, where they capture
antigens, mature and migrate towards lymphoid organs in which
they prime T cells through antigen presentation, cytokine
secretion, and co-stimulatory molecule expression [48]. Our
results corroborate these findings, highlighting the essential role
of DCs in the mechanisms driving protective immunity against
Mtb. We also found that conditioned media from DCs cultured
with BCG and antigens activate NK cells, suggesting that soluble
factors released by DCs are sufficient to activate NK cells. These
results are crucial, given that NK cells are involved in the control
of Mtb infection and activated by Mtb-treated DCs [46,49]. We
showed that among the many soluble factors secreted in culture
media, IL-12 produced upon stimulation of BCG-treated DCs
with HspX and ESAT-6 plays a central role in both CD4+ and
NK cell stimulation. These findings agree with previous studies
showing that IL-12 is the most important cytokine for T cell and
NK cell activation [47].
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Here we also report that inhibition of IL-12 release leads to
increased IL-17AF secretion by T cells cultured with DCs
stimulated with BCG, HspX and ESAT-6. Our results confirm
previous findings that T cells shift from Th1 to Th17 production,
depending on the type of cytokines present in the cell environment
[38,50]. In particular, IL-12 elicits IFN-c secretion [51], whereas
other cytokines, such as IL-1b, IL-23, and IL-6, promote and/or
maintain both IL-17A and IL-17F release [52–54]. Our results
show that DC treatment with BCG, HspX and ESAT-6 induces a
remarkable increase in IL-1b, IL-23 and IL-6 secretion. In spite of
this, the enhanced IL-12 release, obtained in the same exper-
imental conditions, pushes T cells toward a Th1 response,
characterized by IFN-c secretion, and, at the same time, it
inhibits Th17 response characterized by IL-17 production [55].
This finding is remarkable because Th1 cells are known to play an
important role in host defense against Mtb [56]. Although the role
of Th17 in host protection against tuberculosis has not been
completely clarified, it has been shown that the IL-23/Th17
pathway is not crucial for the control of Mtb infection [57];
therefore, the shift from Th17 toward Th1 response, induced upon
HspX and ESAT-6 treatment, might increase the effectiveness of
immune response against Mtb.
Moreover, we have identified the receptors responsible for the
effects of ESAT-6 and HspX on human DCs. Little is known
about the receptors engaged by Mtb antigens. It has been
demonstrated that ESAT-6 and some Mtb heat shock proteins
bind TLR2 [41–43], which is involved in the interaction between
DCs and mycobacteria [44]. Our study shows that TLR2 plays an
important role in the mechanisms by which Mtb, ESAT-6 and
HspX induce IL-12 release and subsequent Th1 response. The
formality of TLR2 recruitment during the coordinated action of
BCG and mycobacterial antigens remains to be characterized and
will be the subject of future investigations. However, our results
highlight that TLR2 participates in the biological events leading to
the activation of immune defense against tuberculosis.
In conclusion, our findings demonstrate that HspX and ESAT-6
cooperate to enhance the capacity of human BCG-primed DCs to
produce IL-12 which, in turn, induces an effective Th1 and NK
cell response. Moreover, the cooperation of HspX, ESAT-6 and
BCG in IL-12 production occurs through TLR2 receptor
engagement. To our knowledge, this is the first evidence that
HspX and ESAT-6 improve the ability of BCG to stimulate
human DC-dependent activation of T lymphocytes and NK cells,
suggesting that these antigens could be used to increase the
immune system’s responsiveness to vaccination with BCG.
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